Antineoplastic drugs that interfere with iron metabolism in cancer cells

Advances in Enzyme Regulation

Volumn 37, Issue , 1997, Pages 147-169

  Head, Jonathan F ^a   Wang, Fen ^a   Elliott, Robert L ^a  

^a The Mastology Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DAUNORUBICIN; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DOXORUBICIN; FLUOROURACIL; GALLIUM; GALLIUM NITRATE; INDIUM; IRON; TRANSFERRIN;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CULTURE; CELL DIVISION; CELL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DIETARY INTAKE; DRUG EFFECT; DRUG MECHANISM; DRUG MIXTURE; DRUG RESEARCH; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IRON METABOLISM; METABOLISM; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CISPLATIN; CLINICAL TRIALS; DAUNORUBICIN; DEFEROXAMINE; FEMALE; GALLIUM; HUMANS; INDIUM; IRON; RATS; TRANSFERRIN; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0030760957     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2571(96)00010-6     Document Type: Conference Paper

References (69)

1. 1. J. BLATT and S. SITELY, Antineuroblastoma activity of desferoxamine in human cell lines, Cancer Res. 47, 1749-1750 (1987).
2. 2. D. L. BECTON and P. BRYLES, Deferoxamine inhibition of human neuroblastoma viability and proliferation, Cancer Res. 48, 7189-7192 (1988).
3. 3. D. L. BECTON and B. ROBERTS, Antileukemic effects of deferoxamine on human myeloid leukemia cell lines, Cancer Res. 49, 4808-4812 (1989).
4. 4. D. L. BECTON and P. BRYLES, Deferoxamine affects viability and clonal growth of human leukemia cells, Clin. Res. 36, A68 (1988).
5. 5. H.-W. L. HANN, M. W. STAHLHUT and C. L. HANN, Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines, Hepatology 11, 566-569 (1990).
6. 6. D. RICHARDSON, P. PONKA and E. BAKER, The effect of the iron (III) chelator, deferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell, Cancer Res. 54, 685-689 (1994).
7. 7. C. BRODIE, G. SIRIWARDANA, J. LUCAS, R. SCHLEICHER, N. TERADA, A. SZEPESI, E, GELFAND and P, SELIGMAN, Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of cell cycle, Cancer Res. 53, 3968-3975 (1993).
8. 8. A. DONFRANCESCO, G. DEB, C. DOMINICI, D. PILEGGI, M. A. CASTELLO and L. HELSON, Effects of a single course of deferoxamine in neuroblastoma patients, Cancer Res. 50, 4929-4930 (1990).
9. 9. A. DONFRANCESCO, G. DEB, C. DOMINICI, A. ANGIONI, M. CANIGLIA, L. DE SIO, P. FIDANI, A. AMICI and L. HELSON, Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma, Am. J. Clin. Oncol. (CCT) 15, 319-322 (1992).
10. 10. C. R. CHITAMBAR and Z. ZIVKOVIC, Uptake of gallium-67 by human leukemic cells: Demonstration of transferrin receptor-dependent and transferrin-independent mechanisms, Cancer Res. 47, 3929-3934 (1987).
11. 11. H. T. WHELAN, C. PRZYBYLSKI and C. R. CHITAMBAR, Differential effects of gallium nitrate on proliferation of brain tumor cells in vitro, Pediatr. Neurol. 7, 23-27 (1991).
12. 12. H. T. WHELAN, C. PRZYBYLSKI and C. R. CHITAMBAR, Alteration of DNA synthesis in human brain tumor cells by gallium nitrate in vitro, Pediatr. Neurol. 7, 352-354 (1991).
13. 13. C. R. CHITAMBAR, J. NARASIMHAN, J. GUY, D. S. SEM and W. J. O'BRIEN, Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells, Cancer Res. 51, 6199-6201 (1991).
14. 14. J. NARASIMHAN, W. E. ANTHOLINE and C. R. CHITAMBAR, Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase, Biochem. Pharmacol. 44, 2403-2408 (1992).
15. 15. C. R. CHITAMBAR, Z. ZIVKOVIC-GILGENBACH, J. NARASIMHAN and W. E. ANTHOLINE, Development of drug resistance to gallium nitrate through modulation of cellular iron uptake, Cancer Res. 50, 4468-4472 (1990).
16. 16. H. T. WHELAN, M. H. SCHMIDT, G. S. ANDERSON, B. K. CHAN, K. HUNTER, D. KUBACKI, A. D. SEGURA and C. R. CHITAMBAR, Antineoplastic effects of gallium nitrate on human medulloblastoma in vivo, Pediatr. Neurol. 8, 323-327 (1992).
17. 17. H. T. WHELAN, M. B. WILLIAMS, D. M. BAJIC, R. E. FLORES, M. H. SCHMIDT, T. L. MCAULIFFE and C. R. CHITAMBAR, Gallium nitrate delays the progression of microscopic disease in a human medulloblastoma murine model, Pediatr. Neurol. 11, 44-46 (1994).
18. 18. H. T. WHELAN, M. B. WILLIAMS, D. M. BAJIC, A. D. SEGURA, T. L. MCAULIFFE and C. R. CHITAMBAR, Prevention of gallium toxicity by hyperhydration in treatment of medulloblastoma, Pediatr. Neurol. 10, 217-220 (1994).
19. 19. J. K. WEICK, R. L. STEPHENS, L. H. BAKER and S. E. JONES, Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study, Cancer Treat. Rep. 67, 823-825 (1983).
20. 20. R. P. WARRELL Jr., C. J. COONLEY, D. J. STRAUS and C. W. YOUNG, Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion, Cancer 51, 1982-1987 (1983).
21. 21. A. SEIDMAN, H. SCHER, C. STERNBERG, D. F. BAJORIN, T. CURLEY, M. SILVERBERG, D. DERSHAW, A. YAGODA and G. J. BOSL, Gallium nitrate (GaN): an active agent in patients (PTS) with advanced refractory transitional cell carcinoma (TCC) of the urothelium, Proc. Annu. Meet. Am. Soc. Clin. Oncol. 10, A520 (1991).
22. 22. A. D. SEIDMAN, H. I. SCHER, M. N. HEINEMANN, D. F. BAJORIN, C. N. STERNBERG, D. D. DERSHAW, M. SILVERBERG and G. J. BOSL, Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors, Cancer 68, 2561-2565 (1991).
23. 23. P. A. SELIGMAN and E. D. CRAWFORD, Treatment of advanced transitional cell carcinoma (TCC) of the bladder with constant infusion gallium nitrate (GA-NITRATE), Proc. Annu. Meet. Am. Soc. Clin. Oncol. 10, A534 (1991).
24. 24. E. D. CRAWFORD, J. H. SAIERS, L. H. BAKER, J. H. COSTANZI and R. M. BUKOWSKI, Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study, Urology 38, 355-357 (1991).
25. 25. J. H. MALFETANO, J. A. BLESSING and M. D. ADELSON, A phase II trial of gallium nitrate (NSC #15200) in previously treated ovarian carcinoma. A Gynecologic Group study, Am. J. Clin. Oncol. 14, 349-351 (1991).
26. 26. J. H. MALFETANO, J. A. BLESSING and H. D. HOMESLEY, A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study, Am. J. Clin. Oncol. 18, 495-497 (1995).
27. 27. J. H. MALFETANO, J. A. BLESSING, H. D. HOMESLEY and P. HANJANI, A phase II trial of gallium nitrate (NSC #15200) in advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study, Invest. New Drugs 9, 109-111 (1991).
28. 28. H. I. SCHER, T. CURLEY, N. GELLER, D. DERSHAW, E. CHAN, J. NISSELBAUM, N. ALCOCK, P. HOLLANDER and A. YAGODA, Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover, Cancer Treat. Rep. 71, 887-893 (1987).
29. 29. W. SULLIVAN, T. GUTHRIE, T. GADDIS and D. SWARTZ, Gallium nitrate (Gn) and doxorubicin (DOX) therapy of hormone refractory prostate cancer (HRPC): effects on parameters of pain, performance status (PS) and prostate-specific antigen (PSA), Proc. Annu. Meet. Am. Soc. Clin. Oncol. 12, A786 (1993).
30. 30. C. J. FABIAN, L. H. BAKER, C. B. VAUGHN and H. E. HYNES, Phase II evaluation of gallium nitrate in breast cancer: a Southwest Oncology Group study, Cancer Treat. Rep. 66, 1591 (1982).
31. 31. K. JABBOURY, D. FRYE, F. A. HOLMES, G. FRASCHINI and G. HORTOBAGYI, Phase II evaluation of gallium nitrate by continuous infusion in breast cancer, Invest. New Drugs 7, 225-229 (1989).
32. 32. J. H. SAIKI, L. H. BAKER, R. L. STEPHENS, C. J. FABIAN, E. H. KRAUT and W. S. FLETCHER, Gallium nitrate in advanced soft tissue and bone sarcomas: a Southwest Oncology Group study, Cancer Treat. Rep. 66, 1673-1674 (1982).
33. 33. S. SCHWARTZ and A. YAGODA, Phase I-II trial of gallium nitrate for advance hypernephroma, Anticancer Res. 4, 317-318 (1984).
34. 34. E. S. CASPER, G. F. STANTON, P. P. SORDILLO, R. PARENTE, R. A. MICHAELSON and V. VINCEGUERRA, Phase II trial of gallium nitrate in patients with advanced malignant melanoma, Cancer Treat. Rep. 69, 1019-2000 (1985).
35. 35. V. CANFIELD and A. P. LYSS, Gallium nitrate (GaN) in metastatic colorectal cancer (CA): preliminary results of a phase II study, Proc. Annu. Meet. Am. Soc. Clin. Oncol. 10, A504 (1991).
36. 36. A. Y. CHANG, Z. N. TU, J. L. SMITH, P. BONOMI, T. J. SMITH, P. H. WIERNIK and R. BLUM, Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588), Invest. New Drugs 13, 137-141 (1995).
37. 37. R. P. Jr. WARRELL, L. DANIEU, C. J. COONLEY and C. ATKINS, Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoguazone, gallium nitrate, and etoposide, Cancer Treat. Rep. 71, 47-51 (1987).
38. 38. P. SCHULTZ, D. BAJORIN, W. K. KELLY, R. MOTZER, G. J. BOSL and H. I. SCHER, Combination gallium nitrate and 5-fluorouracil for platinum-resistant metastatic transitional cell carcinoma of the bladder, Proc. Annu. Meet. Am. Asoc. Cancer Res. 34, A1209 (1993).
39. 39. L. H. EINHORN, B. J. ROTH, R. ANSARI, R. DREICER and P. J. LOEHRER, Vinblastine, ifosfamide and gallium (VIG) combination chemotherapy in urothelial carcinoma, Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13, A702 (1994).
40. 40. L. H. EINHORN, B. J. ROTH, R. ANSARI, R. DREICER, R. GONIN and P. J. LOEHRER, Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma, J. Clin. Oncol. 12, 2271-2276 (1994).
41. 41. L. H. EINHORN, New chemotherapy regimens in metastatic bladder cancer (meeting abstract), Cancer Invest. 13 (suppl. 1), 54-55 (1995).
42. 42. J. MCCAFFREY, S. HILTON, D. BAJORIN, M. MAZUMDAR, A. AMSTERDAM, B. KIM and H. SCHER, Gallium nitrate and 5-fluorouracil combination versus M-Vac (methotrexate, vinblastine, doxorubicin, and cisplatin) in patients with advanced urothelial tract tumors: a Phase II randomized study, Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14, A600 (1995).
43. 43. C. R. CHITAMBAR and P. A. SELIGMAN, Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic H160 cells, J. Clin. Invest. 78, 1538-1546 (1986).
44. 44. C. R. CHITAMBAR, W. G. MATTHAEUS, W. E. ANTHOLINE, K. GRAFF and W. J. O'BRIEN, Inhibition of leukemic H160 cell growth by transferrin-gallium: effects on ribonuclease reductase and demonstration of drug synergy with hydroxyurea, Blood 72, 1930-1936 (1988).
45. 45. R. UL-HAQ and C. R. CHITAMBAR, Modulation of transferrin receptor mRNA by transferrin-gallium in human myeloid H160 and lymphoid CCRF-CEM leukaemic cells, Biochem. J. 294, 873-877 (1993).
46. 46. R. L. ELLIOTT, R. STJERNHOLM and M. C. ELLIOTT, Preliminary evaluation of platinum transferrin (MPTC-63) as a potential nontoxic treatment for breast cancer, Cancer Detect. Prev. 12, 469-480 (1988).
47. 47. T. HOSHINO, M. MISAKI, M. YAMAMOTO, H. SHIMIZU, Y. OGAWA and H. TOGUCHI, In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complexes, J. Pharm. Sci. 84, 216-221 (1995).
48. 48. W. P. FAULK, H. HARATS, J. A. MCINTYRE, A. BERCZI, I. L. SUN and F. L. CRANE, Recent advances in cancer research: drug targeting without the use of monoclonal antibodies, Am. J. Reprod. Immunol. 21, 151-154 (1989).
49. 49. W. P. FAULK, C. G. TAYLOR, C. J. YEH and J. A. MCINTYRE, Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients, Mol. Biother. 2, 57-60 (1990).
50. 50. C. G. TAYLOR, W. P. FAULK and J. M. SARGENT, Clinical study of transferrin-adriamycin conjugate for drug delivery to patients with acute myeloid leukemia (AML), Haematologica 76, 80 (1991).
51. 51. J. A. SIZENSKY, K. BARABAS and W. P. FAULK, Characterization of the anti-cancer activity of transferrin-adriamycin conjugates, Am. J. Reprod. Immunol. 27, 163-166 (1992).
52. 52. M. PAGE and P. LEMIEUX, Sensitivity of resistant MCF-7 cells to a transferrin-doxorubicin conjugate, EACR-12: 12th Biennial Meeting of the European Association for Cancer Research, Brussels, Belgium (1993).
53. 53. T. HATANO, K. OHKAWA and M. MATSUDA, Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro, Tumour Biol. 14, 288-294 (1993).
54. 54. Y. KOHGO, H. KONDO, J. KATO, K. SASAKI, N. TSUSHIMA, T. NISISATO, M. HIRAYAMA, K. FUJIKAWA, N. SHINTANI and Y. MAGI, Kinetics of internalization and cytotoxicity of transferrin-neocarzinostatin conjugate in human leukemia cell line, K562, Jap. J. Cancer Res. 81, 91-99 (1990).
55. 55. N. BEJAOUI, M. PAGE and C. NOEL, Cytotoxicity of transferrin-daunorubicin conjugates on small cell carcinoma of the lung (SCCL) cell line NCI-H69, Anticancer Res. 11, 2211-2213 (1991).
56. 56. R. L. ELLIOTT, M. PAGE and J. F. HEAD, Further evaluation of platinum transferrin (MPTC-63) and daunorubicin transferrin conjugate as potential treatments for breast cancer, Antibody Immunoconj. Radiopharm. 3, 101 (1990).
57. 57. P. LEMIEUX, M. PAGE and C. NOEL, In vivo cytotoxicity and antineoplastic activity of a transferrin-daunorubicin conjugate, In Vivo 6, 621-627 (1992).
58. 58. W. A. HALL, A. GODAL, S. JUELL and O. FODSTAD, In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme, J. Neurosurg. 76, 838-844 (1992).
59. 59. O. FODSTAD, A. T. MYKLEBUST, S. JUELL and A. GODAL, Efficacy of immunotoxins as therapy for human leptomeningeal CNS tumors in nude rats, Proc. Annu. Meet. Am. Assoc. Cancer Res. 35, A3049 (1994).
60. 60. J. F. HEAD and R. L. ELLIOTT, Inhibition of MCF-7 and HeLa cell growth by gallium-and indium-transferrin complexes, Proc. Am. Assoc. Cancer Res. 32, A2298 (1991).
61. 61. J. F. HEAD and R. L. ELLIOTT, Cisplatin-transferrin complex acts synergistically with doxorubicin to inhibit the growth of cultured MCF-7 cells, p. A63 in International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Vol. 6 (1991).
62. 62. R. L. ELLIOTT, M. C. ELLIOTT and J. F. HEAD, Preliminary results of 11 advanced breast cancer patients treated with cisplatin complexed to human transferrin, Breast Cancer Res. Treat. 16, 57 (1990).
63. 63. J. F. HEAD, D. R. NUTT, M. C. ELLIOTT, F. WANG and R. L. ELLIOTT, Phase I/II study of sequentially administered deferoxamine, cisplatin-transferrin complex and FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in advanced breast cancer, Proc. Annu. Meet. Am. Assoc. Cancer Res. 35, A1353 (1994).
64. 64. H.-W. L. HANN, M. W. STAHLUT and H. MEMDUKE, Iron enhances tumor growth: observation on spontaneous mammary tumors in mice, Cancer 68, 2407-2410 (1991).
65. 65. H. W. L. HANN, B. A. STAHLUT and B. S. BLUMBERG, Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice, Cancer Res. 48, 4168-4170 (1988).
66. 66. H.-W. L. HANN, B. A. STAHLUT, R. RUBIN and W. C. MADDREY, Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice, Cancer 70, 2051-2056 (1992).
67. 67. B. ESTROVE, A. TAWA, X. O. H. WANG, I. DUBE, H. SULH, A. COHEN, E. GELFAND and M. FREEDMAN, In vitro and in vivo effects of deferoxamine in neonatal acute leukemia, Blood 69, 757-761 (1987).
68. 68. J. H. LUNDBERG and C. R. CHITAMBAR, Interaction of gallium nitrate and fludarabine and iron chelators: effects on the proliferation of human leukemic H160 cells, Cancer Res. 50, 6466-6470 (1990).
69. 69. F. WANG, J. F. HEAD and R. L. ELLIOTT, The up regulation of transferrin receptors by deferoxamine enhances the growth inhibitory effect of gallium-transferrin on MCF-7 cells, Proc. Am. Assoc. Cancer Res. 37, 2423 (1996).